The role of TGF-β receptors in fibrosis

Open Rheumatology Journal

Volumn 6, Issue 1, 2012, Pages 156-162

  Nakerakanti, Sashidhar ^a   Trojanowska, Maria ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alk1; Endoglin; Erk1 2 MAPK; Fibrosis; PI3K; Smad1; TGF

Indexed keywords

ENDOGLIN; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; SMAD1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION REGULATION; HUMAN; KIDNEY FIBROSIS; LUNG FIBROSIS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS;

EID: 84863920284     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901206010156     Document Type: Review

References (85)

1. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-91.
2. Gordon KJ, Blobe GC. Role of transforming growth factor-beta super family signaling pathways in human disease. Biochim Biophys Acta 2008; 1782: 197-228.
3. Yamamoto T, Noble NA, Cohen AH, et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996; 49: 461-9.
4. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997; 46: 854-9.
5. Coker RK, Laurent GJ, Jeffery PK, et al. Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung. Thorax 2001; 56: 549-56.
6. Ludwicka A, Ohba T, Trojanowska M, et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995; 22: 1876-83.
7. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118: 10-24.
8. Querfeld C, Eckes B, Huerkamp C, et al. Expression of TGF-beta 1,-beta 2 and-beta 3 in localized and systemic scleroderma. J Dermatol Sci 1999; 21: 13-22.
9. Dziadzio M, Smith RE, Abraham DJ, et al. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) 2005; 44: 1518-24.
10. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8: 857-69.
11. Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010; 11: 97-105.
12. Wipff PJ, Hinz B. Integrins and the activation of latent transforming growth factor beta1-an intimate relationship. Eur J Cell Biol 2008; 87: 601-15.
13. Worthington JJ, Klementowicz JE, Travis MA. TGF-beta: a sleeping giant awoken by integrins. Trends Biochem Sci 2011; 36: 47-54.
14. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 2007; 179: 1311-23.
15. Xu MY, Porte J, Knox AJ, et al. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 2009; 174: 1264-79.
16. Mu D, Cambier S, Fjellbirkeland L, et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMPdependent activation of TGF-beta1. J Cell Biol 2002; 157: 493-507.
17. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF-beta activation. J Cell Sci 2003; 116: 217-24.
18. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000; 11: 59-69.
19. Bourd-Boittin K, Bonnier D, Leyme A, et al. Protease profiling of liver fibrosis reveals the ADAM metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of transforming growth factor beta. Hepatology 2011; 54: 2173-84.
20. Asano Y, Ihn H, Jinnin M, et al. Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol 2006; 126: 1761-9.
21. Asano Y, Ihn H, Yamane K, et al. Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGFbeta signaling in scleroderma fibroblasts. J Immunol 2005; 175: 7708-18.
22. Chen Y, Leask A, Abraham DJ, et al. Thrombospondin 1 is a key mediator of transforming growth factor beta-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism. Fibrogenesis Tissue Repair 2011; 4: 9.
23. Mimura Y, Ihn H, Jinnin M, et al. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factorbeta signaling in cultured scleroderma fibroblasts. Am J Pathol 2005; 166: 1451-63.
24. Farina G, Lafyatis D, Lemaire R, et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010; 62: 580-8.
25. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-28.
26. Bourd BK, Bonnier D, Leyme A, et al. Protease profiling of liver fibrosis reveals the adam metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of TGF-beta. Hepatology 2011; 54: 2173-84.
27. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-8.
28. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-71.
29. Zhang W, Jiang Y, Wang Q, et al. Single-molecule imaging reveals transforming growth factor-beta-induced type II receptor dimerization. Proc Natl Acad Sci U S A 2009; 106: 15679-83.
30. Huang T, David L, Mendoza V, et al. TGF-beta signalling is mediated by two autonomously functioning TbetaRI: TbetaRII pairs. EMBO J 2011; 30: 1263-76.
31. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000; 14: 627-44.
32. Kang JS, Liu C, Derynck R. New regulatory mechanisms of TGFbeta receptor function. Trends Cell Biol 2009; 19: 385-94.
33. Mu Y, Gudey SK, Landstrom M. Non-Smad signaling pathways. Cell Tissue Res 2012; 347: 11-20.
34. Trojanowska M. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009; 21: 623-9.
35. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19: 128-39.
36. Caraci F, Gili E, Calafiore M, et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res 2008; 57: 274-82.
37. Kohan M, Muro AF, White ES, et al. EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J 2010; 24: 4503-12.
38. Liu Y, Meyer C, Muller A, et al. IL-13 Induces Connective Tissue Growth Factor in Rat Hepatic Stellate Cells via TGF-{beta}-Independent Smad Signaling. J Immunol 2011; 187: 2814-23.
39. Nagai Y, Miyata K, Sun GP, et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005; 46: 1039-45.
40. Nakerakanti SS, Bujor AM, Trojanowska M. CCN2 is required for the TGF-beta induced activation of Smad1-Erk1/2 signaling network. PLoS One 2011; 6: e21911.
41. Pannu J, Nakerakanti S, Smith E, et al. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 2007; 282: 10405-13.
42. Ponticos M, Holmes AM, Shi-wen X, et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum 2009; 60: 2142-55.
43. Lawler S, Feng XH, Chen RH, et al. The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J Biol Chem 1997; 272: 14850-9.
44. Galliher AJ, Schiemann WP. Src phosphorylates Tyr284 in TGFbeta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 2007; 67: 3752-8.
45. Lee MK, Pardoux C, Hall MC, et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 2007; 26: 3957-67.
46. Samuel GH, Bujor AM, Nakerakanti SS, et al. Autocrine transforming growth factor beta signaling regulates extracellular signal-regulated kinase 1/2 phosphorylation via modulation of protein phosphatase 2A expression in scleroderma fibroblasts. Fibrogenesis Tissue Repair 2010; 3: 25.
47. Griswold PI, Kamibayashi C, Maruoka EM, et al. Physical and functional interactions between type I transforming growth factor beta receptors and Balpha, a WD-40 repeat subunit of phosphatase 2A. Mol Cell Biol 1998; 18: 6595-604.
48. Bandyopadhyay B, Han A, Dai J, et al. TbetaRI/Alk5-independent TbetaRII signaling to ERK1/2 in human skin cells according to distinct levels of TbetaRII expression. J Cell Sci 2011; 124: 19-24.
49. Chen Y, Shi-wen X, Eastwood M, et al. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 2006; 54: 1309-16.
50. Ishida W, Mori Y, Lakos G, et al. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol 2006; 126: 1733-44.
51. Yi JY, Shin I, Arteaga CL. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem 2005; 280: 10870-6.
52. Hong M, Wilkes MC, Penheiter SG, et al. Non-Smad transforming growth factor-beta signaling regulated by focal adhesion kinase binding the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 2011; 286: 17841-50.
53. Wilkes MC, Leof EB. Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem 2006; 281: 27846-54.
54. Gordon J, Spiera R. Imatinib and the treatment of fibrosis: recent trials and tribulations. Curr Rheumatol Rep 2011; 13: 51-8.
55. Bhattacharyya S, Ishida W, Wu M, et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009; 28: 1285-97.
56. Pannu J, Asano Y, Nakerakanti S, et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 2008; 58: 2528-37.
57. Bujor AM, Asano Y, Haines P, et al. The c-Abl tyrosine kinase controls protein kinase Cdelta-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum 2011; 63: 1729-37.
58. Li Z, Jimenez SA. Protein kinase Cdelta and c-Abl kinase are required for transforming growth factor beta induction of endothelial-mesenchymal transition in vitro. Arthritis Rheum 2011; 63: 2473-83.
59. Lamouille S, Derynck R. Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-beta-induced epithelial-mesenchymal transition. Cells Tissues Organs 2011; 193: 8-22.
60. White ES, Atrasz RG, Hu B, et al. Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med 2006; 173: 112-21.
61. Morris E, Chrobak I, Bujor A, et al. Endoglin promotes TGFbeta/Smad1 signaling in scleroderma fibroblasts. J Cell Physiol 2011; 226: 3340-8.
62. Parapuram SK, Shi-Wen X, Elliott C, et al. Loss of PTEN Expression by Dermal Fibroblasts Causes Skin Fibrosis. J Invest Dermatol 2011; 131: 1996-2003.
63. Peyrou M, Bourgoin L, Foti M. PTEN in liver diseases and cancer. World J Gastroenterol 2010; 16: 4627-33.
64. Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2010; 4: 367-88.
65. Fragiadaki M, Mason RM. Epithelial-mesenchymal transition in renal fibrosis-evidence for and against. Int J Exp Pathol 2011; 92: 143-50.
66. Gatza CE, Oh SY, Blobe GC. Roles for the type III TGF-beta receptor in human cancer. Cell Signal 2010; 22: 1163-74.
67. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008; 11: 79-89.
68. Bilandzic M, Stenvers KL. Betaglycan: a multifunctional accessory. Mol Cell Endocrinol 2011; 339: 180-9.
69. Perez-Gomez E, Del Castillo G, Juan Francisco S, et al. The role of the TGF-beta coreceptor endoglin in cancer. Scientific World J 2010; 10: 2367-84.
70. Orlova VV, Liu Z, Goumans MJ, et al. Controlling angiogenesis by two unique TGF-beta type I receptor signaling pathways. Histol Histopathol 2011; 26: 1219-30.
71. Clemente M, Nunez O, Lorente R, et al. Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis. J Viral Hepat 2006; 13: 625-32.
72. Meurer SK, Tihaa L, Borkham KE, et al. Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. Cell Signal 2011; 23: 683-99.
73. Rodriguez PA, Eleno N, Duwell A, et al. Endoglin upregulation during experimental renal interstitial fibrosis in mice. Hypertension 2002; 40: 713-20.
74. Roy CP, Simpson JG, Power DA. Endoglin, a transforming growth factor-beta-binding protein, is upregulated in chronic progressive renal disease. Exp Nephrol 1997; 5: 55-60.
75. Coral APX, Garces MF, Caminos JE, et al. Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. Int J Rheumatol 2010; p. ii: 969383. in press.
76. Dharmapatni AA, Smith MD, Ahern MJ, et al. The TGF beta receptor endoglin in systemic sclerosis. Asian Pac J Allergy Immunol 2001; 19: 275-82.
77. Fujimoto M, Hasegawa M, Hamaguchi Y, et al. A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease. Dermatology 2006; 213: 88-92.
78. Leask A, Abraham DJ, Finlay DR, et al. Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 2002; 46: 1857-65.
79. Morris E, Chrobak I, Bujor A, et al. Endoglin promotes TGFbeta/Smad1 signaling in scleroderma fibroblasts. J Cell Physiol 2011; 226: 3340-8.
80. Wipff J, Avouac J, Borderie D, et al. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford) 2008; 47: 972-5.
81. Velasco S, Alvarez MP, Pericacho M, et al. L-and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci 2008; 121: 913-9.
82. Chen K, Mehta JL, Li D, et al. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res 2004; 95: 1167-73.
83. Hermida N, Lopez B, Gonzalez A, et al. A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 2009; 81: 601-9.
84. Holmes AM, Ponticos M, Shi WX, et al. Elevated CCN2 expression in scleroderma: a putative role for the TGFbeta accessory receptors TGFbetaRIII and endoglin. J Cell Commun Signal 2011; 5: 173-7.
85. Varga J, Pasche B. Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr Opin Rheumatol 2008; 20: 720-8.